PMA device
VENTANA PD-L1 (SP263) Assay
Ventana Medical Systems, Inc. · Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS, Class III) · First FDA decision May 1, 2017, newest Mar 1, 2023Cancer detection and genomic testingLung cancer and lung nodules
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
1
Naming "VENTANA PD-L1"
MAUDE reports
30
Brand "VENTANA PD-L1", since 2015
PubMed studies
69
Mentioning "VENTANA PD-L1"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VENTANA PD-L1 (SP263) Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- VENTANA PD-L1 (SP263) AssayPMA supplement
P160046-S013 · Decided Mar 1, 2023 · 314 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- VENTANA PD-L1 (SP263) AssayPMA supplement
P160046-S010 · Decided Oct 15, 2021 · 123 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- Ventana PD-L1 (SP263)PMA supplement
P160046-S004 · Decided Jun 1, 2018 · 59 days after receipt · Normal 180 Day Track No User Fee
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P160002-S002
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VENTANA PD-L1", any status and sponsor, newest update first.
National Cancer Institute (NCI)NIH
NCT05642195 · 30 participants (planned) · Start Nov 24, 2026 · Primary completion Dec 30, 2033
Device: Ventana PD-L1 (SP263 or SP142) assay · For: Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung and 1 more
Sites: Bethesda, Maryland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VENTANA PD-L1", and for the whole product code for context.
This brand
30 reports: 30 malfunction, 0 injury, 0 death
Whole product code PLS
35 reports: 34 malfunction, 1 injury, 0 death
Newest reports for this brand
- VENTANA PD-L1 (SP263) CE IVD US ExportMalfunction
2028492-2026-04067 · Received Oct 2, 2026 · Event dated Sep 9, 2026
Device type: Immunohistochemistry Reagents And Kits (NJT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- VENTANA PD-L1 (SP142) ASSAYMalfunction
2028492-2023-03954 · Received Dec 12, 2023 · Event dated Dec 5, 2023
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- VENTANA PD-L1 (SP142) ASSAYMalfunction
2028492-2023-03168 · Received Oct 3, 2023 · Event dated Sep 4, 2023
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: False Negative Result
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "VENTANA PD-L1"[tiab]. The summary above synthesizes these.
- Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab.
Moehler M, Yoon HH, Wagner DC, et al. · Mod Pathol · 2025
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, et al. · Ann Oncol · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.
Williams GH, Nicholson AG, Snead DRJ, et al. · J Thorac Oncol · 2020Research Support, Non-U.S. Gov't
- PD-L1 assessment in urothelial carcinoma: a practical approach.
Eckstein M, Cimadamore A, Hartmann A, et al. · Ann Transl Med · 2019Review
- Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay.
D'Abbronzo G, Lucà S, Cioce A, et al. · Expert Rev Mol Diagn · 2026Review
- PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
Gupta G, Pasricha S, Kamboj M, et al. · Indian J Pathol Microbiol · 2022
- Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
Badve SS, Penault-Llorca F, Reis-Filho JS, et al. · J Natl Cancer Inst · 2022Research Support, Non-U.S. Gov't
- Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A, Ashok Kumar P, Sokol ES, et al. · Cancer Med · 2021Research Support, Non-U.S. Gov't
- Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
Perez J, Kerr KM, Baker B, et al. · JCO Precis Oncol · 2025Clinical Trial, Phase III, Multicenter Study
- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D, Yokoi T, McCleod MJ, et al. · Clin Lung Cancer · 2016Clinical Trial, Phase III, Multicenter Study
- Nods for Atezolizumab and Nivolumab from FDA.
Cancer Discov · 2016
- Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
Erber R, Hartmann A · Breast Care (Basel) · 2020Review
Other devices of this type
Also filed under product code PLS.
- PD-L1 IHC 22C3 pharmDxAgilent Technologies, Inc. · PMA 2026
- PD-L1 IHC 28-8 pharmDxAgilent Technologies, Inc. · PMA 2026
- VENTANA PD-L1 (SP263) CDx AssayVentana Medical Systems, Inc. · PMA 2024
- PD-L1 Ihc 28-8 PharmdxDako North America, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.